메뉴 건너뛰기




Volumn 22, Issue 6, 2008, Pages 815-821

Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies

Author keywords

Adverse events; Complications; Dose; Gastrointestinal; Intolerance; Mycophenolate mofetil; Side effects

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; TACROLIMUS;

EID: 56349154980     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00892.x     Document Type: Article
Times cited : (48)

References (55)
  • 1
    • 33645694582 scopus 로고    scopus 로고
    • Immunosuppression: Evolution in practice and trends, 1994-2004
    • Meier-Kriesche HU, Li S, Gruessner RW et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006: 6: 1111.
    • (2006) Am J Transplant , vol.6 , pp. 1111
    • Meier-Kriesche, H.U.1    Li, S.2    Gruessner, R.W.3
  • 2
    • 0029006409 scopus 로고
    • Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
    • European Mycophenolate Mofetil Cooperative Study Group
    • European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995: 345: 1321.
    • (1995) Lancet , vol.345 , pp. 1321
  • 3
    • 0029115531 scopus 로고
    • Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group
    • Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995: 60: 225.
    • (1995) Transplantation , vol.60 , pp. 225
    • Sollinger, H.W.1
  • 4
    • 0006986048 scopus 로고    scopus 로고
    • A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
    • Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group
    • Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996: 61: 1029.
    • (1996) Transplantation , vol.61 , pp. 1029
  • 5
    • 0034660104 scopus 로고    scopus 로고
    • Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection
    • Ojo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000: 69: 2405.
    • (2000) Transplantation , vol.69 , pp. 2405
    • Ojo, A.O.1    Meier-Kriesche, H.U.2    Hanson, J.A.3
  • 6
    • 0031024728 scopus 로고    scopus 로고
    • Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups
    • Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997: 63: 39.
    • (1997) Transplantation , vol.63 , pp. 39
    • Halloran, P.1    Mathew, T.2    Tomlanovich, S.3    Groth, C.4    Hooftman, L.5    Barker, C.6
  • 7
    • 0346525123 scopus 로고    scopus 로고
    • Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection
    • Meier-Kriesche HU, Steffen BJ, Hochberg AM et al. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 2003: 3: 68.
    • (2003) Am J Transplant , vol.3 , pp. 68
    • Meier-Kriesche, H.U.1    Steffen, B.J.2    Hochberg, A.M.3
  • 8
    • 0034654107 scopus 로고    scopus 로고
    • Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group
    • Miller J, Mendez R, Pirsch JD, Jensik SC. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000: 69: 875.
    • (2000) Transplantation , vol.69 , pp. 875
    • Miller, J.1    Mendez, R.2    Pirsch, J.D.3    Jensik, S.C.4
  • 9
    • 56349147470 scopus 로고    scopus 로고
    • Nutley, NJ, USA: Roche Pharmaceuticals. Revised October
    • MMF Prescribing Information. Nutley, NJ, USA: Roche Pharmaceuticals. Revised October 2005.
    • (2005) MMF Prescribing Information
  • 10
    • 0042536429 scopus 로고    scopus 로고
    • Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation
    • Knoll GA, Mac Donald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003: 14: 2381.
    • (2003) J Am Soc Nephrol , vol.14 , pp. 2381
    • Knoll, G.A.1    Mac Donald, I.2    Khan, A.3    Van Walraven, C.4
  • 12
    • 28644442483 scopus 로고    scopus 로고
    • Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal recipients
    • Tierce JC, Porterfield-Baxa J, Petrilla AA, Kilburg A, Ferguson RM. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal recipients. Clin Transplant 2005: 19: 779.
    • (2005) Clin Transplant , vol.19 , pp. 779
    • Tierce, J.C.1    Porterfield-Baxa, J.2    Petrilla, A.A.3    Kilburg, A.4    Ferguson, R.M.5
  • 13
    • 0034889041 scopus 로고    scopus 로고
    • Adverse gastrointestinal effects of mycophenolate mofetil: Aetiology, incidence and management
    • B ehrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001: 24: 645.
    • (2001) Drug Saf , vol.24 , pp. 645
    • Behrend, M.1
  • 15
    • 33750587517 scopus 로고    scopus 로고
    • Using GI-specific patient outcome measures in renal transplant patients: Validation of the GSRS and GIQLI
    • Kleinman L, Kilburg A, Machnicki G et al. Using GI-specific patient outcome measures in renal transplant patients: Validation of the GSRS and GIQLI. Qual Life Res 2006: 15: 1223.
    • (2006) Qual Life Res , vol.15 , pp. 1223
    • Kleinman, L.1    Kilburg, A.2    Machnicki, G.3
  • 16
    • 0041360482 scopus 로고    scopus 로고
    • Overview of large database analysis in renal transplantation
    • Kaplan B, Schold J, Meier-Kriesche HU. Overview of large database analysis in renal transplantation. Am J Transplant 2003: 3: 1052.
    • (2003) Am J Transplant , vol.3 , pp. 1052
    • Kaplan, B.1    Schold, J.2    Meier-Kriesche, H.U.3
  • 17
    • 12144273473 scopus 로고    scopus 로고
    • Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil
    • Hardinger K, Brennan DC, Lowell J, Schnitzler M. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transplant Int 2004: 17: 609.
    • (2004) Transplant Int , vol.17 , pp. 609
    • Hardinger, K.1    Brennan, D.C.2    Lowell, J.3    Schnitzler, M.4
  • 18
    • 33747494883 scopus 로고    scopus 로고
    • Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure
    • Bunnapradist S, Lentine KL, Burroughs TE et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006: 82: 102.
    • (2006) Transplantation , vol.82 , pp. 102
    • Bunnapradist, S.1    Lentine, K.L.2    Burroughs, T.E.3
  • 19
    • 51749098832 scopus 로고    scopus 로고
    • Gastrointestinal event associated dose reduction and discontinuation of renal transplant patients receiving MMF
    • Legoretta AP, Robinson M, Gilmore AS, Feng S. Gastrointestinal event associated dose reduction and discontinuation of renal transplant patients receiving MMF. Transplantation 2006: 82(Suppl. 3): 485.
    • (2006) Transplantation , vol.82 , Issue.SUPPL. 3 , pp. 485
    • Legoretta, A.P.1    Robinson, M.2    Gilmore, A.S.3    Feng, S.4
  • 20
    • 35748956704 scopus 로고    scopus 로고
    • A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients
    • Takemoto SK, Pinsky BW, Schnitzler MA et al. A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients. Am J Transplant 2007: 7: 2704.
    • (2007) Am J Transplant , vol.7 , pp. 2704
    • Takemoto, S.K.1    Pinsky, B.W.2    Schnitzler, M.A.3
  • 21
    • 56349121245 scopus 로고    scopus 로고
    • Diarrhea following renal transplantation: Influences of immunosuppression and implications for survival
    • Salvalaggio P, Pinsky B, Takemoto SK et al. Diarrhea following renal transplantation: Influences of immunosuppression and implications for survival. Transplantation 2006: 82(Suppl. 3): 480.
    • (2006) Transplantation , vol.82 , Issue.SUPPL. 3 , pp. 480
    • Salvalaggio, P.1    Pinsky, B.2    Takemoto, S.K.3
  • 22
    • 56349115925 scopus 로고    scopus 로고
    • Graft outcomes and healthcare costs in kidney transplant recipients who develop diarrhea or dyspepsia and discontinue use of mycophenolate mofetil
    • Legoretta AP, Kang N, Gilmore AS et al. Graft outcomes and healthcare costs in kidney transplant recipients who develop diarrhea or dyspepsia and discontinue use of mycophenolate mofetil. Transplantation 2006: 82(Suppl. 3): 484.
    • (2006) Transplantation , vol.82 , Issue.SUPPL. 3 , pp. 484
    • Legoretta, A.P.1    Kang, N.2    Gilmore, A.S.3
  • 23
    • 33745810228 scopus 로고    scopus 로고
    • Severe diarrhea in renal transplant patients: Results of the DIDACT study
    • Maes B, Hadaya K, de Moor B et al. Severe diarrhea in renal transplant patients: Results of the DIDACT study. Am J Transplant 2006: 6: 1466.
    • (2006) Am J Transplant , vol.6 , pp. 1466
    • Maes, B.1    Hadaya, K.2    de Moor, B.3
  • 24
    • 33751527410 scopus 로고    scopus 로고
    • Improvement in social functioning in kidney transplant patients after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®): Three case studies
    • Shah T. Improvement in social functioning in kidney transplant patients after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®): Three case studies. Drugs 2006: 66 (Suppl. 2): 15.
    • (2006) Drugs , vol.66 , Issue.SUPPL. 2 , pp. 15
    • Shah, T.1
  • 25
    • 33751539416 scopus 로고    scopus 로고
    • Resolution of gastrointestinal side effects in a patient converted from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®)
    • Tuncer M. Resolution of gastrointestinal side effects in a patient converted from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®). Drugs 2006: 66(Suppl. 2): 9.
    • (2006) Drugs , vol.66 , Issue.SUPPL. 2 , pp. 9
    • Tuncer, M.1
  • 27
    • 33750953529 scopus 로고    scopus 로고
    • Consequences of immunosuppression minimization following diagnosis of gastrointestinal complications in renal transplant
    • Schnitzler MA, Hardinger KL, Burroughs TE, Irish WD, Lentine K, Brennan D. Consequences of immunosuppression minimization following diagnosis of gastrointestinal complications in renal transplant. Am J Transplant 2005: 5(Suppl. 11): 242.
    • (2005) Am J Transplant , vol.5 , Issue.SUPPL. 11 , pp. 242
    • Schnitzler, M.A.1    Hardinger, K.L.2    Burroughs, T.E.3    Irish, W.D.4    Lentine, K.5    Brennan, D.6
  • 28
    • 0033609476 scopus 로고    scopus 로고
    • A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation
    • van Gelder T, Hilbrands LB, Vanrenterghem Y et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999: 68: 261.
    • (1999) Transplantation , vol.68 , pp. 261
    • van Gelder, T.1    Hilbrands, L.B.2    Vanrenterghem, Y.3
  • 29
    • 27644434992 scopus 로고    scopus 로고
    • The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation
    • van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 2005: 80: S244.
    • (2005) Transplantation , vol.80
    • van Gelder, T.1    Shaw, L.M.2
  • 30
    • 33846591856 scopus 로고    scopus 로고
    • Non-infectious gastrointestinal complications of mycophenolic acid therapy: A consequence of local GI toxicity?
    • Arns W. Non-infectious gastrointestinal complications of mycophenolic acid therapy: A consequence of local GI toxicity? Transplant Proc 2007: 39: 88.
    • (2007) Transplant Proc , vol.39 , pp. 88
    • Arns, W.1
  • 31
    • 15844416494 scopus 로고    scopus 로고
    • Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil
    • Arns W, Breuer S, Choudhury S et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005: 19: 199.
    • (2005) Clin Transplant , vol.19 , pp. 199
    • Arns, W.1    Breuer, S.2    Choudhury, S.3
  • 32
    • 1342346699 scopus 로고    scopus 로고
    • Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients
    • On Behalf of the ERLB301 Study Group
    • Salvadori M, Holzer H, de Mattos A et al, On Behalf of the ERLB301 Study Group. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004: 4: 231.
    • (2004) Am J Transplant , vol.4 , pp. 231
    • Salvadori, M.1    Holzer, H.2    de Mattos, A.3
  • 33
    • 33747104149 scopus 로고    scopus 로고
    • Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic®) is safe in kidney transplant patients
    • On Behalf of the ERL B301 Study Group
    • Salvadori M, Holzer H, Civati G et al. On Behalf of the ERL B301 Study Group. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic®) is safe in kidney transplant patients. Clinical Nephrol 2006: 66: 112.
    • (2006) Clinical Nephrol , vol.66 , pp. 112
    • Salvadori, M.1    Holzer, H.2    Civati, G.3
  • 34
    • 1342325540 scopus 로고    scopus 로고
    • Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study
    • On behalf of the ERL B302 Study Group
    • Budde K, Curtis J, Knoll G et al. On behalf of the ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study. Am J Transplant 2004: 4: 237.
    • (2004) Am J Transplant , vol.4 , pp. 237
    • Budde, K.1    Curtis, J.2    Knoll, G.3
  • 35
    • 33747119649 scopus 로고    scopus 로고
    • Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS, myfortic®)
    • Budde K, Knoll G, Curtis J et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS, myfortic®). Clin Nephrol 2006: 66: 103.
    • (2006) Clin Nephrol , vol.66 , pp. 103
    • Budde, K.1    Knoll, G.2    Curtis, J.3
  • 36
    • 33750950096 scopus 로고    scopus 로고
    • Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: Results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine
    • ERL2405-DE02 Study Group
    • Nashan B, Suwelack B, Ivens K et al. ERL2405-DE02 Study Group. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: Results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine. Transplant Proc 2006: 38: 2856.
    • (2006) Transplant Proc , vol.38 , pp. 2856
    • Nashan, B.1    Suwelack, B.2    Ivens, K.3
  • 37
    • 17844395233 scopus 로고    scopus 로고
    • Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients
    • myPROMS LatAm Study Group
    • Massari P, Duro-Garcia V, Girón F et al. myPROMS LatAm Study Group. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients. Transplant Proc 2005: 37: 916.
    • (2005) Transplant Proc , vol.37 , pp. 916
    • Massari, P.1    Duro-Garcia, V.2    Girón, F.3
  • 38
    • 33746473566 scopus 로고    scopus 로고
    • Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: Results of a 12-month, single-blind, randomized, parallel-group, multicenter study
    • Kobashigawa JA, Renlund DG, Gerosa G et al. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant 2006: 25: 935.
    • (2006) J Heart Lung Transplant , vol.25 , pp. 935
    • Kobashigawa, J.A.1    Renlund, D.G.2    Gerosa, G.3
  • 39
    • 33744494308 scopus 로고    scopus 로고
    • Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium
    • Chan L, Mulgaonkar S, Walker R, Arns W, Ambühl P, Schiavelli R. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006: 81: 1290.
    • (2006) Transplantation , vol.81 , pp. 1290
    • Chan, L.1    Mulgaonkar, S.2    Walker, R.3    Arns, W.4    Ambühl, P.5    Schiavelli, R.6
  • 40
    • 37349015946 scopus 로고    scopus 로고
    • Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients
    • Bolin P, Tanriover B, Zibari GB et al. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation 2007: 84: 1443.
    • (2007) Transplantation , vol.84 , pp. 1443
    • Bolin, P.1    Tanriover, B.2    Zibari, G.B.3
  • 41
    • 27144546807 scopus 로고    scopus 로고
    • Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium
    • Kamar N, Oufroukhi L, Faure P et al. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium. Nephrol Dial Transplant 2005: 20: 2231.
    • (2005) Nephrol Dial Transplant , vol.20 , pp. 2231
    • Kamar, N.1    Oufroukhi, L.2    Faure, P.3
  • 42
    • 33746700882 scopus 로고    scopus 로고
    • Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in patients with gastrointestinal side effects: Case studies
    • Boswell A, Rigg K, Shehata M. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in patients with gastrointestinal side effects: Case studies. Prog Transplant 2006: 16: 138.
    • (2006) Prog Transplant , vol.16 , pp. 138
    • Boswell, A.1    Rigg, K.2    Shehata, M.3
  • 43
    • 33751501957 scopus 로고    scopus 로고
    • Complete resolution of severe diarrhoea after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®) in a patient at high immunological risk
    • Breidenbach T, Spangenberg M, Nagel E. Complete resolution of severe diarrhoea after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®) in a patient at high immunological risk. Drugs 2006: 66(Suppl. 2): 25.
    • (2006) Drugs , vol.66 , Issue.SUPPL. 2 , pp. 25
    • Breidenbach, T.1    Spangenberg, M.2    Nagel, E.3
  • 44
    • 56349110073 scopus 로고    scopus 로고
    • Dose and dose adjustments of mycophenolate sodium (EC-MPS, myfortic) and mycophenolate mofetil (MMF) in de novo renal transplant patients
    • On Behalf of the Direct Study Group
    • Budde K, Tuncer M, El-Shahawy M, On Behalf of the Direct Study Group. Dose and dose adjustments of mycophenolate sodium (EC-MPS, myfortic) and mycophenolate mofetil (MMF) in de novo renal transplant patients. Transplantation 2006: 82(Suppl. 3): 345.
    • (2006) Transplantation , vol.82 , Issue.SUPPL. 3 , pp. 345
    • Budde, K.1    Tuncer, M.2    El-Shahawy, M.3
  • 45
    • 33748804924 scopus 로고    scopus 로고
    • Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: A pilot study
    • Dumortier J, Gagnieu M-C, Salandre J et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: A pilot study. Liver Transplant 2006: 12: 1342.
    • (2006) Liver Transplant , vol.12 , pp. 1342
    • Dumortier, J.1    Gagnieu, M.-C.2    Salandre, J.3
  • 46
    • 26644469263 scopus 로고    scopus 로고
    • Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data
    • Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. Br Med J 2005: 331: 810.
    • (2005) Br Med J , vol.331 , pp. 810
    • Webster, A.C.1    Woodroffe, R.C.2    Taylor, R.S.3    Chapman, J.R.4    Craig, J.C.5
  • 47
    • 0030836803 scopus 로고    scopus 로고
    • Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection
    • Mayer AD, Dmitrewski J, Squifflet J-P et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997: 64: 436.
    • (1997) Transplantation , vol.64 , pp. 436
    • Mayer, A.D.1    Dmitrewski, J.2    Squifflet, J.-P.3
  • 48
    • 0031001622 scopus 로고    scopus 로고
    • A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
    • For the FK506 kidney transplant study group
    • Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. For the FK506 kidney transplant study group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997: 63: 977.
    • (1997) Transplantation , vol.63 , pp. 977
    • Pirsch, J.D.1    Miller, J.2    Deierhoi, M.H.3    Vincenti, F.4    Filo, R.S.5
  • 49
    • 0036943134 scopus 로고    scopus 로고
    • Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation
    • Trompeter R, Filler G, Webb NJA et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002: 17: 141.
    • (2002) Pediatr Nephrol , vol.17 , pp. 141
    • Trompeter, R.1    Filler, G.2    Webb, N.J.A.3
  • 50
    • 0027141042 scopus 로고
    • Erythromycin and other macrolides as prokinetic agents
    • Peeters TL Erythromycin and other macrolides as prokinetic agents. Gastroenterology 1993: 105: 1886.
    • (1993) Gastroenterology , vol.105 , pp. 1886
    • Peeters, T.L.1
  • 51
    • 22244431879 scopus 로고    scopus 로고
    • Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate
    • Kaplan B, Meier-Kriesche HU, Minnick P et al. Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate. Clin Transplant 2005: 19: 551.
    • (2005) Clin Transplant , vol.19 , pp. 551
    • Kaplan, B.1    Meier-Kriesche, H.U.2    Minnick, P.3
  • 53
    • 0038001525 scopus 로고    scopus 로고
    • Two- to three-fold increase in blood tacrolimus (FK506) level during diarrhea in liver-transplanted children
    • Berenguer JI, López-Espinosa JA, Ortega-López J et al. Two- to three-fold increase in blood tacrolimus (FK506) level during diarrhea in liver-transplanted children. Clin Transplant 2003: 17: 249.
    • (2003) Clin Transplant , vol.17 , pp. 249
    • Berenguer, J.I.1    López-Espinosa, J.A.2    Ortega-López, J.3
  • 54
    • 0036870921 scopus 로고    scopus 로고
    • Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients
    • Maes BD, Lemahieu W, Kuypers D et al. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. Am J Transplant 2002: 2: 989.
    • (2002) Am J Transplant , vol.2 , pp. 989
    • Maes, B.D.1    Lemahieu, W.2    Kuypers, D.3
  • 55
    • 4344561078 scopus 로고    scopus 로고
    • Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: A prospective study in one hundred de novo renal transplant recipients
    • Kuypers DRJ, Claes K, Evenepoel P et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: A prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet 2004: 43: 741.
    • (2004) Clin Pharmacokinet , vol.43 , pp. 741
    • Kuypers, D.R.J.1    Claes, K.2    Evenepoel, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.